Top Page
Indaptus Therapeutics
(NASDAQ:INDP)
Indaptus Therapeutics (INDP) vs. SPDR S&P 500 ETF (SPY)
Indaptus Therapeutics Business Overview & Revenue Model
Indaptus Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -16.91M | -15.37M | -16.38M | -14.91M | -7.73M | -3.60M |
| Net Income | -16.87M | -15.02M | -15.42M | -14.32M | -7.71M | -3.58M |
Balance Sheet | ||||||
| Total Assets | 6.84M | 7.34M | 14.92M | 28.06M | 40.58M | 1.78M |
| Cash, Cash Equivalents and Short-Term Investments | 5.83M | 5.79M | 13.36M | 26.43M | 39.13M | 1.64M |
| Total Debt | 8.69K | 84.16K | 175.05K | 80.49K | 169.33K | 0.00 |
| Total Liabilities | 2.23M | 3.39M | 2.85M | 3.43M | 4.68M | 2.02M |
| Stockholders Equity | 4.61M | 3.94M | 12.08M | 24.63M | 35.90M | -237.70K |
Cash Flow | ||||||
| Free Cash Flow | -15.52M | -12.32M | -13.41M | -13.25M | -11.29M | -3.32M |
| Operating Cash Flow | -15.52M | -12.32M | -13.41M | -13.08M | -11.29M | -3.32M |
| Investing Cash Flow | 0.00 | 0.00 | 17.14M | -16.43M | 447.75K | 0.00 |
| Financing Cash Flow | 13.96M | 4.75M | 0.00 | 0.00 | 48.34M | 1.16M |
Indaptus Therapeutics Technical Analysis
Indaptus Therapeutics Risk Analysis
Indaptus Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $247.35M | -0.39 | -228.64% | ― | ― | 71.95% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $7.43M | -0.11 | -317.98% | ― | ― | 34.57% | |
45 Neutral | $6.87M | -1.33 | -145.65% | ― | ― | 68.59% | |
42 Neutral | $5.54M | -1.18 | -57.43% | ― | 13.30% | 22.70% |
Indaptus Therapeutics Corporate Events
On January 8, 2026, Indaptus Therapeutics, Inc. expanded its Board of Directors from eight to nine members and appointed David Natan as a Class II director, with a term running until the 2026 annual meeting of stockholders. Natan, designated under a December 22, 2025 securities purchase agreement by investor David E. Lazar, brings extensive executive, financial, and public company board experience, including leadership roles in consulting, energy, pharmaceuticals, technology, and prior tenure at Deloitte & Touche. He was simultaneously named to the Audit Committee, replacing Avraham Ben-Tzvi in that role, while Ben-Tzvi will remain on the Board as a director and is expected to serve as a paid consultant, and the Board has determined that Natan meets Nasdaq’s independence and heightened audit committee independence requirements and will be compensated under the company’s non-employee director compensation plan.
The most recent analyst rating on (INDP) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.
On December 29, 2025, Indaptus Therapeutics, Inc. announced that three members of its Board of Directors — Michael Newman, Mark Gilbert and Anthony Maddaluna — submitted their resignations, to be effective upon the approval of David Lazar’s nominees at the company’s next stockholders’ meeting. The company stated that these resignations were not due to any disagreement with management, the board or its committees regarding the company’s operations, policies or practices, indicating an orderly governance transition rather than a response to internal conflict.
The most recent analyst rating on (INDP) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.
On December 22–23, 2025, Indaptus Therapeutics raised $6 million through a private sale of 300,000 shares of Series AA Convertible Preferred Stock and 700,000 shares of Series AAA Convertible Preferred Stock to investor David E. Lazar at $6.00 per share, securities that are ultimately convertible into a combined 111 million shares of common stock and rank senior to common equity in a liquidation. The company plans to use the proceeds for ongoing operations, severance and general corporate purposes, and has committed to seek shareholder approval by March 31, 2026 for a series of governance and capital structure actions, including authorizing sufficient common shares for conversion, permitting written shareholder consents, adding three Lazar designees to the board and executing a reverse stock split, while granting Lazar participation rights for up to 25% of future equity offerings during a six‑month period. The financing coincided with significant leadership changes: directors Robert Martell and Hila Karah resigned following approval of the offering; Lazar was installed as chairman and co‑chief executive officer and joined on the board by attorney and capital markets specialist Avraham Ben‑Tzvi, while existing director Roger Pomerantz remained on the board and took on key committee roles. In parallel, the company renegotiated terms with its executive team—reducing notice periods and waiving severance in exchange for a mix of cash and equity settlements, securing their voting support for the upcoming shareholder meeting, and accepted the year‑end resignation of its chief medical officer, actions that collectively underscore a broad recapitalization and governance reset aimed at stabilizing the balance sheet and aligning control with the new lead investor.
The most recent analyst rating on (INDP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.